Prognostic-related biomarker RRM2 and corresponding targeted drug clofarabine in cervical squamous cell carcinoma
MedBA Medicine · 30.06.2026 · 2 (1) · 55-61
DOI: 10.65079/mbam06 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedBA Medicine, online erschienen am 30.06.2026. Verfasst von Yan Wang und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cervical squamous cell carcinoma (CESC) is a disease that occurs in the female reproductive system. Once diagnosed as cervical cancer, current treatment methods have limitations in improving the prognostic survival rate of patients. Therefore, looking for new biomarker or targeted drug has become an effective treatment of CESC.
Methods
The gene expression profile GSE7803 was downloaded from the Gene Expression Omnibus (GEO). The differentially expressed mRNAs (DEMs) between cervical cancer tissues and normal tissues was screened by adjust p 1.0. Next, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analysis were performed on these DEMs. Then, the hub gene in PPINs was identified through the MCODE plug-in Cytoscape. Besides, survival analysis and drug gene network interaction was executed in GEPIA and DGI database respectively.
Results
A total of 699 DEMs were identified, including 362 up-regulated and 337 down-regulated DEMs. GO of DEMs are mainly involved in cell division, extracellular space, and protein binding, while KEGG pathway of DEMs are mainly related to Cell cycle, DNA replication, and p53 signaling pathway. In addition, there are 27 central genes were identified, and the survival analysis indicated the overall survival of cervical cancer patients with relative high RRM2 expression is significantly decreased compared to that with relative low RRM2 expression. At the same time, the expression level of the RRM2 in CESC dataset built-in GEPIA2 is consistent with the expression level in GSE7803. Finally, using the DGI database, six small molecules were identified as potential targeted drugs for the treatment of cervical cancer.
Conclusion
The RRM2 gene and candidate drugs might improve the individualized diagnosis target and treatment of cervical cancer patients in the future. Keywords: Cervical cancer, Microarray, Bioinformatics analysis, Differentially expressed mRNAs
Zitieren
APA
Wang, Y., & Xiao, Z. (2026). Prognostic-related biomarker RRM2 and corresponding targeted drug clofarabine in cervical squamous cell carcinoma. MedBA Medicine, 2(1), 55-61. https://doi.org/10.65079/mbam06
Vancouver
Wang Y, Xiao Z. Prognostic-related biomarker RRM2 and corresponding targeted drug clofarabine in cervical squamous cell carcinoma. MedBA Medicine. 2026;2(1):55-61. doi:10.65079/mbam06
BibTeX
@article{Wang2026,
author = {Wang, Yan and Xiao, Zhiming},
title = {Prognostic-related biomarker RRM2 and corresponding targeted drug clofarabine in cervical squamous cell carcinoma},
journal = {MedBA Medicine},
year = {2026},
volume = {2},
number = {1},
pages = {55--61},
doi = {10.65079/mbam06}
}
EUVIMED